Recipient sensitization is a major risk factor of antibody-mediated rejection (ABMR) and inferior graft survival. The predictive effect of solid-phase human leukocyte antigen antibody testing and flow cytometry crossmatch (FCXM) in the era of peritransplant desensitization remains poorly understood. This observational retrospective single-center study with 108 donor-specific antibody (DSA)-positive deceased donor kidney allograft recipients who had undergone peritransplant desensitization aimed to analyze variables affecting graft outcome. ABMR rates were highest among patients with positive pretransplant FCXM vs. FCXM-negative (76 vs. 18.7%, p < 0.001) and with donor-specific antibody mean fluorescence intensity (DSA MFI) > 5,000 vs. <5,000 (54.5 vs. 28%, p = 0.01) despite desensitization. In univariable Cox regression, FCXM positivity, retransplantation, recipient gender, immunodominant DSA MFI, DSA number, and peak panel reactive antibodies were found to be associated with ABMR occurrence. In multivariable Cox regression adjusted for desensitization treatment (AUC = 0.810), only FCXM positivity (HR = 4.6, p = 0.001) and DSA number (HR = 1.47, p = 0.039) remained significant. In conclusion, our data suggest that pretransplant FCXM and DSA number, but not DSA MFI, are independent predictors of ABMR in patients who received peritransplant desensitization.

Aesculab Pathology Prague Czechia

Department of Computer Science Faculty of Electrical Engineering Czech Technical University Prague Czechia

Department of Immunogenetics Institute for Clinical and Experimental Medicine Prague Czechia

Department of Nephrology Institute for Clinical and Experimental Medicine Prague Czechia

Department of Pathology Institute for Clinical and Experimental Medicine Prague Czechia

Department of Transplant Surgery Institute for Clinical and Experimental Medicine Prague Czechia

Division of Nephrology and Dialysis Department of Medicine 3 Medical University Vienna Vienna Austria

Transplant Laboratory Institute for Clinical and Experimental Medicine Prague Czechia

Zobrazit více v PubMed

Amico P, Honger G, Mayr M, Steiger J, Hopfer H, Schaub S. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation. (2009) 87:1681–8. 10.1097/TP.0b013e3181a5e034 PubMed DOI

Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, Antoine C, et al. . Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol. (2010) 21:1398–406. 10.1681/ASN.2009101065 PubMed DOI PMC

Loupy A, Hill GS, Jordan SC. The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol. (2012) 8:348–57. 10.1038/nrneph.2012.81 PubMed DOI

Caro-Oleas JL, Gonzalez-Escribano MF, Gonzalez-Roncero FM, Acevedo-Calado MJ, Cabello-Chaves V, Gentil-Govantes MA, et al. . Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation. Nephrol Dial Transplant. (2012) 27:1231–8. 10.1093/ndt/gfr429 PubMed DOI

Gloor JM, Winters JL, Cornell LD, Fix LA, DeGoey SR, Knauer RM, et al. . Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant. (2010) 10:582–9. 10.1111/j.1600-6143.2009.02985.x PubMed DOI

Dunn TB, Noreen H, Gillingham K, Maurer D, Ozturk OG, Pruett TL, et al. . Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant. (2011) 11:2132–43. 10.1111/j.1600-6143.2011.03640.x PubMed DOI PMC

Orandi BJ, Chow EH, Hsu A, Gupta N, Van Arendonk KJ, Garonzik-Wang JM, et al. . Quantifying renal allograft loss following early antibody-mediated rejection. Am J Transplant. (2015) 15:489–98. 10.1111/ajt.12982 PubMed DOI PMC

O'Leary JG, Samaniego M, Barrio MC, Potena L, Zeevi A, Djamali A, et al. . The influence of immunosuppressive agents on the risk of de novo donor-specific HLA antibody production in solid organ transplant recipients. Transplantation. (2016) 100:39–53. 10.1097/TP.0000000000000869 PubMed DOI PMC

Schwaiger E, Eskandary F, Kozakowski N, Bond G, Kikic Z, Yoo D, et al. . Deceased donor kidney transplantation across donor-specific antibody barriers: predictors of antibody-mediated rejection. Nephrol Dial Transplant. (2016) 31:1342–51. 10.1093/ndt/gfw027 PubMed DOI

Couzi L, Araujo C, Guidicelli G, Bachelet T, Moreau K, Morel D, et al. . Interpretation of positive flow cytometric crossmatch in the era of the single-antigen bead assay. Transplantation. (2011) 91:527–35. 10.1097/TP.0b013e31820794bb PubMed DOI

Adebiyi OO, Gralla J, Klem P, Freed B, Davis S, Wiseman AC, et al. . Clinical significance of pretransplant donor-specific antibodies in the setting of negative cell-based flow cytometry crossmatching in kidney transplant recipients. Am J Transplant. (2016) 16:3458–67. 10.1111/ajt.13848 PubMed DOI

Schinstock CA, Gandhi M, Cheungpasitporn W, Mitema D, Prieto M, Dean P, et al. . Kidney transplant with low levels of DSA or low positive B-Flow crossmatch: an underappreciated option for highly sensitized transplant candidates. Transplantation. (2017) 101:2429–39. 10.1097/TP.0000000000001619 PubMed DOI PMC

Loupy A, Haas M, Roufosse C, Naesens M, Adam B, Afrouzian M, et al. . The banff 2019 kidney meeting report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant. (2020) 20:2318–31. 10.1111/ajt.15898 PubMed DOI PMC

Song X, Zhou X-H. A semiparametric approach for the covariate specific ROC curve with survival outcome. Statistica Sinica. (2008) 18:947–65. Available online at: http://www3.stat.sinica.edu.tw/statistica/oldpdf/A18n37.pdf

Caillard S, Becmeur C, Gautier-Vargas G, Olagne J, Muller C, Cognard N, et al. . Pre-existing donor-specific antibodies are detrimental to kidney allograft only when persistent after transplantation. Transpl Int. (2017) 30:29–40. 10.1111/tri.12864 PubMed DOI

Zecher D, Bach C, Staudner C, Boger CA, Bergler T, Banas B, et al. . Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen. Nephrol Dial Transplant. (2017) 32:730–7. 10.1093/ndt/gfw445 PubMed DOI

Jordan SC, Ammerman N, Choi J, Huang E, Peng A, Sethi S, et al. . Novel therapeutic approaches to allosensitization and antibody-mediated rejection. Transplantation. (2019) 103:262–72. 10.1097/TP.0000000000002462 PubMed DOI

Montgomery RA, Loupy A, Segev DL. Antibody-mediated rejection: new approaches in prevention and management. Am J Transplant. (2018) 18 Suppl 3:3–17. 10.1111/ajt.14584 PubMed DOI

Slatinska J, Honsova E, Burgelova M, Slavcev A, Viklicky O. Plasmapheresis and intravenous immunoglobulin in early antibody-mediated rejection of the renal allograft: a single-center experience. Ther Apher Dial. (2009) 13:108–12. 10.1111/j.1744-9987.2009.00664.x PubMed DOI

Turgeon NA, Kirk AD, Iwakoshi NN. Differential effects of donor-specific alloantibody. Transplant Rev. (2009) 23:25–33. 10.1016/j.trre.2008.08.001 PubMed DOI

Viglietti D, Lefaucheur C, Glotz D. Evidence for an important role of both complement-binding and noncomplement-binding donor-specific antibodies in renal transplantation. Curr Opin Organ Transplant. (2016) 21:433–40. 10.1097/MOT.0000000000000324 PubMed DOI

El-Awar N, Jucaud V, Nguyen A. HLA epitopes: the targets of monoclonal and alloantibodies defined. J Immunol Res. (2017) 2017:3406230. 10.1155/2017/3406230 PubMed DOI PMC

Duquesnoy RJ. HLA epitope based matching for transplantation. Transpl Immunol. (2014) 31:1–6. 10.1016/j.trim.2014.04.004 PubMed DOI

Konvalinka A, Tinckam K. Utility of HLA antibody testing in kidney transplantation. J Am Soc Nephrol. (2015) 26:1489–502. 10.1681/ASN.2014080837 PubMed DOI PMC

Tait BD. Detection of HLA antibodies in organ transplant recipients - triumphs and challenges of the solid phase bead assay. Front Immunol. (2016) 7:570. 10.3389/fimmu.2016.00570 PubMed DOI PMC

Bachelet T, Martinez C, Del Bello A, Couzi L, Kejji S, Guidicelli G, et al. . Deleterious impact of donor-specific anti-HLA antibodies toward HLA-Cw and HLA-DP in kidney transplantation. Transplantation. (2016) 100:159–66. 10.1097/TP.0000000000000821 PubMed DOI

Orandi BJ, Garonzik-Wang JM, Massie AB, Zachary AA, Montgomery JR, Van Arendonk KJ, et al. . Quantifying the risk of incompatible kidney transplantation: a multicenter study. Am J Transplant. (2014) 14:1573–80. 10.1111/ajt.12786 PubMed DOI

Orandi BJ, Luo X, Massie AB, Garonzik-Wang JM, Lonze BE, Ahmed R, et al. . Survival benefit with kidney transplants from HLA-incompatible live donors. N Engl J Med. (2016) 374:940–50. 10.1056/NEJMoa1508380 PubMed DOI PMC

Orandi BJ, Zachary AA, Dagher NN, Bagnasco SM, Garonzik-Wang JM, Van Arendonk KJ, et al. . Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation. Transplantation. (2014) 98:857–63. 10.1097/TP.0000000000000298 PubMed DOI

Amrouche L, Aubert O, Suberbielle C, Rabant M, Van Huyen JD, Martinez F, et al. . Long-term outcomes of kidney transplantation in patients with high levels of preformed DSA: the necker high-risk transplant program. Transplantation. (2017) 101:2440–8. 10.1097/TP.0000000000001650 PubMed DOI

Viklicky O, Fronek J, Trunecka P, Pirk J, Lischke R. Organ transplantation in the Czech Republic. Transplantation. (2017) 101:2259–61. 10.1097/TP.0000000000001871 PubMed DOI

Viklicky O, Krivanec S, Vavrinova H, Berlakovich G, Marada T, Slatinska J, et al. . Crossing borders to facilitate live donor kidney transplantation: the Czech-Austrian kidney paired donation program - a retrospective study. Transpl Int. (2020) 33:1199–210. 10.1111/tri.13668 PubMed DOI

Transcriptomic Signatures of Antibody-mediated Rejection in Early Biopsies With Negative Histology in HLA-incompatible Kidney Transplantation